Galderma has reached into its bag of trademarks and announced that Mirvaso will be known as ONRELTEA in Canada.
Health Canada Approves The First and Only Topical Treatment Indicated for the Persistent Facial Erythema of Rosacea
THORNHILL, ON, May 21, 2014 /CNW/ –
Galderma Canada Inc., today announced that ONRELTEA™ topical gel (Brimonidine gel 0.33%) has been approved by Health Canada and is now available for Canadian patients 18 and older to treat the facial erythema (redness) of rosacea. ONRELTEA is the first and only Health Canada-approved topical prescription specifically designed to treat the facial redness of rosacea.
“Despite the many rosacea treatment advancements, patients were still left without any options when it came to controlling the redness, which is a common characteristic of the inflammatory skin disorder that affects more than 2 million Canadians,” says Dr. Jason Rivers, dermatologist in Vancouver and President of the Acne and Rosacea Society of Canada. “Redness is by far the most bothersome symptom for rosacea patients and ONRELTEA has been shown to reduce redness for up to 12 hours.”
“Developing rosacea in my forties was a challenging ordeal – the flare ups were embarrassing and my face would be covered in redness, which was so frustrating for me,” says Danette Larabie. “Onreltea was the only treatment that ever really worked for me, it totally eliminated the redness and I am overjoyed that it is now available for other patients like me.”
For more information about ONRELTEA, see the product monograph at: http://www.galderma.ca/pm/onreltea.pdf
Galderma is following a tradition of naming products differently for the Canadian market – Oracea is known Apprilon in Canada.